CurveBeam AI Ltd (ASX: CVB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
CurveBeam AI Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$36.31 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
477.73 million
Earnings per share
-0.045
Dividend per share
N/A
Year To Date Return
2.70%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
CurveBeam AI Ltd (ASX: CVB)
Latest News
Small Cap Shares
Bell Potter is tipping huge returns from these small cap ASX shares
CVB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About CurveBeam AI Ltd
CurveBeam AI Ltd is a manufacturer of specialized imaging equipment that has developed software that, through the use of artificial intelligence (AI), and deep learning AI (DLAI), automates the scan processing and analysis of the high-quality images produced from the company's CT devices to assist in the clinical assessment. The company has one operating segment, being the research, design, manufacture and sale of cone beam CT imaging equipment for orthopaedic specialties, which includes the development, validation and preparation for commercialisation of a HRpQCT Medical Device and Software as a Service (SaaS) platform.
CVB Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 09 Feb 2026 | $0.08 | $0.00 | 0.00% | 1,830,829 | $0.08 | $0.08 | $0.08 |
| 06 Feb 2026 | $0.08 | $0.00 | 0.00% | 477,245 | $0.08 | $0.08 | $0.08 |
| 05 Feb 2026 | $0.08 | $0.00 | 0.00% | 423,008 | $0.08 | $0.08 | $0.08 |
| 04 Feb 2026 | $0.08 | $0.00 | 0.00% | 254,167 | $0.08 | $0.08 | $0.08 |
| 03 Feb 2026 | $0.08 | $0.00 | 0.00% | 162,010 | $0.08 | $0.08 | $0.08 |
| 02 Feb 2026 | $0.08 | $-0.01 | -12.20% | 2,244,624 | $0.09 | $0.09 | $0.08 |
| 30 Jan 2026 | $0.08 | $0.00 | 0.00% | 1,450,105 | $0.09 | $0.09 | $0.08 |
| 29 Jan 2026 | $0.09 | $0.01 | 12.66% | 1,256,503 | $0.08 | $0.09 | $0.08 |
| 28 Jan 2026 | $0.08 | $0.00 | 0.00% | 487,188 | $0.08 | $0.08 | $0.08 |
| 27 Jan 2026 | $0.08 | $0.00 | 0.00% | 223,103 | $0.08 | $0.08 | $0.08 |
| 23 Jan 2026 | $0.08 | $0.00 | 0.00% | 153,642 | $0.08 | $0.08 | $0.08 |
| 22 Jan 2026 | $0.08 | $0.00 | 0.00% | 1,027,184 | $0.08 | $0.08 | $0.08 |
| 21 Jan 2026 | $0.08 | $0.00 | 0.00% | 534,083 | $0.08 | $0.08 | $0.08 |
| 20 Jan 2026 | $0.08 | $0.00 | 0.00% | 652,533 | $0.08 | $0.08 | $0.08 |
| 19 Jan 2026 | $0.08 | $0.00 | 0.00% | 316,485 | $0.08 | $0.08 | $0.08 |
| 16 Jan 2026 | $0.08 | $0.00 | 0.00% | 400,327 | $0.08 | $0.08 | $0.08 |
| 15 Jan 2026 | $0.08 | $0.00 | 0.00% | 449,375 | $0.08 | $0.08 | $0.08 |
| 14 Jan 2026 | $0.08 | $0.00 | 0.00% | 593,183 | $0.08 | $0.08 | $0.08 |
| 13 Jan 2026 | $0.08 | $0.00 | 0.00% | 258,957 | $0.08 | $0.08 | $0.08 |
| 12 Jan 2026 | $0.08 | $0.00 | 0.00% | 611,004 | $0.08 | $0.09 | $0.08 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 05 Dec 2025 | Arun Singh | Buy | 408,415 | $29,518 |
On-market trade.
|
| 14 Aug 2025 | Arun Singh | Exercise | 131,237 | $23,622 |
Conversion of securities.
|
| 14 Aug 2025 | Robert Lilley | Issued | 63,918 | $12,499 |
Conversion of securities.
|
| 14 Aug 2025 | Gregory Brown | Exercise | 127,400 | $22,932 |
Conversion of securities.
|
| 14 Aug 2025 | Arun Singh | Issued | 131,237 | $23,622 |
Conversion of securities.
|
| 14 Aug 2025 | Robert Lilley | Exercise | 63,918 | $12,499 |
Conversion of securities.
|
| 14 Aug 2025 | Gregory Brown | Issued | 127,400 | $22,932 |
Conversion of securities.
|
| 24 Mar 2025 | Robert Lilley | Exercise | 82,148 | $21,250 |
Conversion of securities. 191,754 Share Rights
|
| 24 Mar 2025 | Robert Lilley | Buy | 82,148 | $21,250 |
Conversion of securities.
|
| 24 Mar 2025 | Arun Singh | Exercise | 268,840 | $107,804 |
Conversion of securities. 131237 Rights
|
| 24 Mar 2025 | Arun Singh | Buy | 268,840 | $107,804 |
Conversion of securities.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Gregory Wayne Brown | Chief Executive OfficerManaging Director | Oct 2014 |
Mr Brown has over 35 years of experience in the healthcare industry, with a focus on medical devices and personalised medicine. Prior to joining CurveBeam, he held marketing roles at Baxter Diagnostics. He is also a director of Cintra Consulting Pty Ltd and has previously served as a director of Trinity Biotech plc. He is also a director of an Australian management consulting company, Cintra Consulting Pty Ltd.
|
| Mr Robert Lilley | Non-Executive ChairmanNon-Executive Director | Apr 2021 |
Mr Lilley has over 35 years of experience in the medical device and diagnostics industries. He previously served as senior vice president of global sales and marketing for Digene Corporation, a molecular diagnostics company later acquired by Qiagen N.V. He is currently the Chair of Immunexpress Pty Ltd, an Australian molecular diagnostics company. He is also member of Risk committee.
|
| Mr Arun Singh | Chief Operating OfficerChief Technology OfficerExecutive DirectorPresident | Mar 2023 |
Mr Singh has over 34 years of experience in the advanced imaging technology industry, with a focus on medical imaging. Since 2009, he has served as President and Chief Executive Officer of CurveBeam US. Before this, he co-founded and served as Vice President and Chief Technology Officer of Imaging Sciences International Inc., which was later acquired by Danaher Corporation. He received the Lifetime Achievement Award from the American Association of Dental Maxillofacial Radiographic Technicians in 2016 for his contributions to cone beam CT technology.
|
| Mr Hashan De Silva | Non-Executive Director | Oct 2021 |
Mr Sliva is the Founder and Managing Partner of KP Rx, a healthcare fund manager focused on companies based in Australia and New Zealand. Previously, he served as head of healthcare research at Karst Peak, an investment management firm based in Sydney and Hong Kong with a focus on biotechnology, health technology, medical devices, and diagnostics. He is also member of Risk committee.
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Citicorp Nominees Pty Limited | 75,797,330 | 19.28% |
| Hsbc Custody Nominees (Australia) Limited | 32,778,055 | 8.34% |
| Arun Singh | 21,825,529 | 5.55% |
| Kp Tmf Asa | 20,615,746 | 5.24% |
| HSBC Custody Nominees (Australia) Limited A/C | 13,477,574 | 3.43% |
| Gregory Wayne Brown | 11,342,091 | 2.88% |
| Amal Security Services Pty Limited | 11,111,111 | 2.83% |
| Susmita Singh | 10,776,511 | 2.74% |
| HSBC Custody Nominees (Australia) Limited A/C | 9,226,081 | 2.35% |
| J P Morgan Nominees Australia Pty Limited | 8,370,721 | 2.13% |
| Bnp Paribas Nominees Pty Ltd | 8,297,175 | 2.11% |
| Capital M Group Ii Llc | 4,891,426 | 1.24% |
| Gregory Wayne Brown (i) | 4,542,500 | 1.16% |
| Seego Pty Ltd | 4,094,528 | 1.04% |
| Bnp Paribas Noms Pty Ltd | 3,775,289 | 0.96% |
| Uwe Mundry and Sigrid Mundry | 3,461,203 | 0.88% |
| Um Commercialisation Pty Ltd | 3,260,000 | 0.83% |
| Robert Mcg Lilley | 3,157,502 | 0.80% |
| Mabre Superannuation Pty Ltd | 3,007,050 | 0.76% |
| Francois Lintz | 2,942,060 | 0.75% |
